Skip to main content
Figure 3 | Arthritis Research & Therapy

Figure 3

From: CD56+ monocytes have a dysregulated cytokine response to lipopolysaccharide and accumulate in rheumatoid arthritis and immunosenescence

Figure 3

CD14bright/CD56+ monocyte subset decreases during therapeutic tumor necrosis factor blockade. (a) Peripheral blood frequencies of CD14bright/CD56+ monocytes in 16 RA patients before and after treatment with etanercept. (b) Change in Disease Activity Score in 28 joints (∆DAS28) and CD14bright/CD56+ monocyte frequency at week 12 of treatment with etanercept (Enbrel) correlated to baseline (n = 16).

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us